Bristol-Myers Squibb Company Revenue and Competitors
Estimated Revenue & Valuation
- Bristol-Myers Squibb Company's estimated annual revenue is currently $45.5B per year.
- Bristol-Myers Squibb Company's estimated revenue per employee is $1,167,424
- Bristol-Myers Squibb Company's total funding is $6.1B.
- Bristol-Myers Squibb Company's current valuation is $144.1B. (January 2022)
Employee Data
- Bristol-Myers Squibb Company has 38949 Employees.
- Bristol-Myers Squibb Company grew their employee count by 4% last year.
Bristol-Myers Squibb Company's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Executive Associate II to VP, Worldwide HEOR Markets - US | Reveal Email/Phone |
3 | VP | Reveal Email/Phone |
4 | Executive Associate to VP and Department Head | Reveal Email/Phone |
5 | Executive Administrative Aide to the VP Worldwide Hematology, Value, Access, & Pricing | Reveal Email/Phone |
6 | Associate to the VP Hematology Finance | Reveal Email/Phone |
7 | cso technician ll | Reveal Email/Phone |
8 | Executive Director Business Development, Translational Medicine | Reveal Email/Phone |
9 | Chief Staff, Global Regulatory Sciences (Secondment) | Reveal Email/Phone |
10 | Executive Director - Oncology, Hematology and Cell Therapy Business Development Transactions | Reveal Email/Phone |
Bristol-Myers Squibb Company Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 25 | -11% | N/A | N/A |
#2 | $35.8M | 178 | 8% | N/A | N/A |
#3 | $5.4M | 27 | -25% | N/A | N/A |
#4 | $4180M | 14516 | 1% | $550M | N/A |
#5 | $12.5M | 62 | 15% | N/A | N/A |
#6 | $6.7M | 119 | -37% | $199.6M | N/A |
#7 | $9.4M | 47 | 7% | N/A | N/A |
#8 | $10.3M | 51 | 6% | N/A | N/A |
#9 | $106.3M | 529 | 16% | N/A | N/A |
#10 | $15.5M | 77 | 20% | N/A | N/A |
What Is Bristol-Myers Squibb Company?
Bristol-Myers Squibb Company, through its divisions and subsidiaries, is a producer and distributor of consumer medicines, pharmaceuticals, nutritionals, medical devices and beauty care products. For the fiscal year ended 12/31/01, net sales rose 7% to $19.42 billion. Net income from continuing operations fell 38% to $2.53 billion. Results reflect increased volume and selling prices of pharmaceutical products, offset by the inclusion of a $2.74 billion acquired R&D charge.
keywords:N/A
$6.1B
Total Funding
38949
Number of Employees
$45.5B
Revenue (est)
4%
Employee Growth %
$144.1B
Valuation
N/A
Accelerator
Bristol-Myers Squibb Company News
Bristol Myers Squibb Co. closed $0.57 below its 52-week high ($78.13), which the company achieved on April 11th. The stock outperformed some of...
Bristol-Myers Squibb Co. (BMY) shares closed today at 0.7% below its 52 week high of $78.13, giving the company a market cap of $168B. The...
The stock's rise snapped a two-day losing streak. Bristol Myers Squibb Co. closed $0.85 short of its 52-week high ($78.13), which the company...
MONTREAL, Nov. 2, 2021 /CNW/ - Today Bristol Myers Squibb Canada announces two recent Health Canada approvals for OPDIVO® (nivolumab). Unlike traditional cancer therapies that target tumours directly, OPDIVO® activates the body's own immune system to help recognize and attack cancer cells. On O ...